## Loughborough University The Centre for Biological Engineering

Safety Dep't' Use Only	Material(s) Classification	on
Ref No:	Hazard Group 1	$\boxtimes$
	Hazard Group 2	
CBE Use Only		
Ref No:	GMO [	
CBE/BRA/160	HTA Licensable	$\boxtimes$

Person conducting this risk assessment

FORM CBE-RA-FORM/002. Version 8.0

## RISK ASSESSMENT AND PROJECT REGISTRATION FOR WORK INVOLVING BIOLOGICAL MATERIAL

## PLEASE READ CAREFULLY

**Principal Investigator** 

This form acts to register projects involving the use of Biological Agents and / or Genetically Modified Micro-Organisms, or of materials that may be contaminated with these agents. It assesses the hazards and risks associated with the project as well as identifying those at risk and the measures necessary for preventing, or controlling these risks. Please ensure that sufficient detail is provided when completing this form and that the relevant written SOPs are referenced where required. Once completed and approved, all risk assessments must be supplied to all those working within this project. The work described within this form must not commence until this risk assessment has been completed and approved and that all necessary control measures are in place.

Any changes to the work, or the persons involved, must be notified to the departmental Quality Manager (dQM). All changes requested must be recorded within the risk assessment change control form and may also need to be incorporated within an amended version of this form.

A separate risk assessment will be required for assessing risks associated with GMO activities.

Name: Dr Elizabeth Ratcliffe		ET 19 Leaves	Name:	Dr Elizabet	h Ratcliffe					
Position	ion Lecturer			Position	Lecturer					
Department: Chemical engineering			Department:	Chemical e	ngineering					
School:		Chemical eng	ineering		School:	Chemical e	ngineering	Review date Click here to enter a date.  Click here to enter a date.		
The Pro	ject Acti	vitv	,		Risk Assessme	ent Change His	story			
			asts		Date:	ID & Version		Review date		
Title: Storage of dermal fibroblasts		na varanji su (A	Click here to enter a date.		489	Click here to				
Referer	ice No:									
Start:	03/05/20	18	End:	30/11/2021		2002				
The follo	owing dec	laration must be	comple	ted and undersigned by the	Principal Investigato	or or Person Res	sponsible for the	project		
⊠All inf ⊠All wo ⊠All wo assessed ⊠All wo ⊠It is un Gorm eit ⊠All ch	ormation orkers invo orkers hav i orkers hav nderstood her taking	contained in this blved will be inst e been given, or e, or will be befo I that this risk ass responsibility fo he work covered	s form is a ructed the will be given their in sessment or the new sessment.	accurate and comprehensive at their work must remain we wen before they become involvement begins, enrolled shall not be transferred to a wactivities, or ensuring that orm will be reassessed & the Signature:	ithin the boundaries olved, adequate train with Occupational H third party without a new proposal is sul changes submitted	of this project in of this project in the second where dealth for health the PI/Supervise bmitted	registration & ass necessary their con n clearance where or/Line Manager	essment ompetency e necessary named in this		
Duralo -	mandatory	,	White	- for all work	Pink = cells, tissues, k	oody fluids or	Groon - non Chi	hiological agents		
ruipie =	manuatory		Aviiite.	TOT All WOLK			Green = non-Giv	biological agents		

	This section must be completed						
INTRODUCTION	1.1. Background & aim of project	dermal (location Howeve	Storage of dermal fibroblasts only. Currently the CBE has 1 cryovial dermal fibroblast cells which will are being stored in the cryobank (location B7/R3/BXA1). No work is currently planned for their use. However, when future work is planned, a full risk assessment will be carried out				
Z	1.2. Description of experimental procedur		erimental pro he cryobank		are to be performed, on	ly storage of cells	
	1.3. Where will this work be carried out?				ntre for Biological Engine	ering	
		Building	g(s): Garrenc	lon wing	, Holywell Park		
		Campus	: Loughbord	ough Uni	versity		
	<b>NOTE:</b> A brief background to the project provid	les the reviewer a h	etter underst	andina of	the aims of the work For O	1.2 the author is	
	encouraged to cover as much of their activities laboratory procedures to be used and highlight documentation i.e. protocols).	with a particular m	naterial or bio	logical ag	ent as possible within this fo	orm. Describe	
2.	If this material is to be used then all releva	nt parts of this s	ection must	be comp	oleted		
NA.	TISSUES, CELLS, BODY FLUIDS OR EXCRETA						
TURE C	2.1. If human or animal tissues, cells, body 2.11.	fluids or excreta v	vill NOT be ι	ised ther	hatch here $\square$ and proce .	eed to section	
¥	2.2. List all cells, tissues, body fluid or excre	THE CHIPMEN PRODUCTION OF THE CHIPMEN CONTRACTOR CONTRA	Carcarde the Unit Carcar Carton				
OR!	Material type	Organ source	Species	Text of the second	e will it be obtained from He country of origin)		
NATURE OF WORK & HAZARD IDENTIFICAT	1. Primary Dermal fibroblasts	Skin	Human	-	C (UK), Product Code PCS-201-011, Lot		
ZARI	2.			144.5			
D ID	3.       4.						
EN	5.						
	2.3. Is any material listed in section 2.2 con 2004?* If No, proceed to section 2.4	sidered to be 'rel	evant mater	ial' unde	r the Human Tissue Act	⊠Yes □No	
N N	2.3.1. List all HTA relevant material and ind			ase tick	all appropriate boxes)		
		Source/Provide					
		A=Commercial:		h RFC ar	pproval for generic resear	ch use: C=Other	
	Relevant Material type	HTA licensed or			provarjor generio rescur	en use, e e ener	
			with REC a	pproval f	or research use;		
		E=Imported			<u> </u>		
	1. Primary Dermal fibroblasts					•	
	3.						
	4.						
	5.	□а□в□с					
	* See https://www.hta.gov.uk/policies/list-materials-o 2004#sthash.EliTXrB3.dpuf	considered-be-%E2%8	0%98relevant-	material%E	2%80%99-under-human-tissue	-act-	
	2.4. Has any material listed in section 2.2 b	een genetically m	odified in				
	any way?	cen genericany m	ounieu iii	□Yes ⊠No	Ref No:		
D)	If Yes, complete GMO Risk Assessment Forn			△ INO			
	2.5 Has any of the material listed in section						
	list of cross-contaminated/ misidentified ce (http://www.hpacultures.org.uk/media/E5			□Yes			
	aminations v6 0.pdf	or any cell tille C	1033 CUIIL	⊠No	• 4 - 1-10 (0.1 1-10) - 1-10		
	If Yes, provide details of the route of prove	nance back to the	originator	□N/R			
	of the cell line, together with a Certificate o						

2.0	thods used to qualify the cell type.						
infe	Has any of the material listed in section 2.2 been screened for ctious/communicable disease agents eg HIV, HBV, HCV, TSEs, H If Yes, provide details.	TLV	⊠Yes □No	includ fungi/	ing ster mycopl		(bacteria/yeast/ CR virus testing
2.7.	2.7. Will any clinical history or veterinary screening be provided? □Yes ⋈No □N/R						
2	2.7.1. If Yes, detail what this will include:						
The second second second	2.7.2. If Yes, will a policy of rejection of samples from diseased donors be adopted? Explain:						
100000000000000000000000000000000000000	2.7.3. If Yes, and for human material, how will the information be disseminated in the course of the project?	oe				□ N/F	₹ .
2	2.7.4. If Yes and for human material, will this information be anonymised?	□Yes □	No		□N/F	₹ '	
	What is the likelihood of infection of any of this material? Cons worst case if multiple materials are to be used.	ider	□Mediu □High R Go to Q2	isk .		⊠Low □Nor Go to	ne
	If medium or high risk of infection - name and classify the ogical agents this material could be infected with		Material Agent: ACDP/De Classifica	fra			
	D. Describe the type and severity of the disease that can be caus umans or animals by each of the agents that could be present.	ed				t .	
	LOGICAL AGENTS (i.e. micro-organisms such as bacteria, viruse	es. fun	gi, micros	copic e	ndopara	asites)	
The second second	. If non-Genetically Modified biological agent will NOT be used					the specific territories	ion 3.1
	2. List the biological agents to be used		ne of ager	The second secon	Strain(s		ACDP/Defra classification
caus	B. Describe the type & severity of the disease that can be sed to humans, animals or plants by each of the agents and if want, the particular strains in use e.g. colonisation, infection, rgy, toxin-mediated disease						
244							
mod	I. Has any strain listed in section 2.12 been genetically dified in any way?  Proceed the GMO Risk Assessment form	□Υ	es 🗆 No		Ref No		
mod If Ye	lified in any way?	□Υ	es 🗆 No		Ref No	•	
mod If Ye.	dified in any way? es, complete the GMO Risk Assessment form	□Υ	es 🗆 No		Ref No	:	
mod If Ye.	dified in any way? es, complete the GMO Risk Assessment form section must be completed in all cases  SSIFICATION OF HAZARD GROUP  Are you confident that any non-GM organism, tissue, cell, body aponent thereof covered by this assessment cannot potentially processing the section of the sectio	fluid,	excreta o		S X	Yes* - Cl	lassify as HG1
This  CLAS  3.1.  com or ca  t	dified in any way?  ss, complete the GMO Risk Assessment form  section must be completed in all cases  SSIFICATION OF HAZARD GROUP  Are you confident that any non-GM organism, tissue, cell, body aponent thereof covered by this assessment cannot potentially pause human diseases?  3:1.1. If No, can any non-GM organism, tissue, cell, body fluid, ethereof cause human disease and potentially be a hazard to hur	r fluid, pose a xcreta mans b	excreta o threat to or any co out is unlik	human: mponei	s 🗆	Yes* - Cl   No   Yes - Cla	lassify as HG1
This  CLAS  3.1. com or ca  t s t	dified in any way?  Is, complete the GMO Risk Assessment form  Section must be completed in all cases  SSIFICATION OF HAZARD GROUP  Are you confident that any non-GM organism, tissue, cell, body aponent thereof covered by this assessment cannot potentially pause human diseases?  3.1.1. If No, can any non-GM organism, tissue, cell, body fluid, ethereof cause human disease and potentially be a hazard to hurst spread to the community and for which there is usually effective treatment available?  3.1.2. If No, can any non-GM organism, tissue, cell, body fluid, ethereof cause severe human disease and potentially be a seriou that may spread to the community, where effective prophylaxis	y fluid, pose a xcreta mans b e prop xcreta s haza	excreta of threat to or any coput is unlike hylaxis or or any copring to hum	mponer ely to mponer ans and	s	Yes* - Cl   No   Yes - Cla   No	ssify as HG2  D NOT USE
This CLAS 3.1. com or ca tt ss tt r 3.2.	dified in any way?  Is, complete the GMO Risk Assessment form  Section must be completed in all cases  SSIFICATION OF HAZARD GROUP  Are you confident that any non-GM organism, tissue, cell, body apponent thereof covered by this assessment cannot potentially pause human diseases?  3:1.1. If No, can any non-GM organism, tissue, cell, body fluid, eathereof cause human disease and potentially be a hazard to hur spread to the community and for which there is usually effective treatment available?  3:1.2. If No, can any non-GM organism, tissue, cell, body fluid, eathereof cause severe human disease and potentially be a seriou	r fluid, pose a xcreta nans b e prop xcreta s haza or tre	excreta o threat to or any co out is unlik hylaxis or or any co ord to hum eatment m	mponer ely to mponer ans and ay or m	s	Yes* - Cla No Yes - Cla No Yes - DC Onsult the	D NOT USE
This CLAS 3.1. com or ca tt ss tt r 3.2. and	dified in any way?  Is, complete the GMO Risk Assessment form  Section must be completed in all cases  SSIFICATION OF HAZARD GROUP  Are you confident that any non-GM organism, tissue, cell, body aponent thereof covered by this assessment cannot potentially pause human diseases?  B.1.1. If No, can any non-GM organism, tissue, cell, body fluid, exthereof cause human disease and potentially be a hazard to hurst spread to the community and for which there is usually effective treatment available?  B.1.2. If No, can any non-GM organism, tissue, cell, body fluid, exthereof cause severe human disease and potentially be a serious that may spread to the community, where effective prophylaxis not be available?  Do any of the materials contain pathogens or toxins covered by Security Act?  PIE: PLEASE READ CAREFULLY  must only answer 'YES' to question 3.1 if you believe that you have suffits risk assessment would be of no or of negligible risk to human health	r fluid, pose a xcreta nans be prop xcreta or tre	excreta on threat to or any concur is unlike hylaxis or or any concurd to humbatment mathematical information	mponer ely to mponer ans anc ay or m	nt	Yes* - Cla   No   Yes - Cla   No   Yes - DO   Onsult the	O NOT USE DSO  NOT USE DSO  A NOT USE DSO  A caterial(s) covered
This  CLAS  3.1. com or ca  t s t t r 3.2. and  *NO Your by th biolo	dified in any way?  Is, complete the GMO Risk Assessment form  Section must be completed in all cases  SSIFICATION OF HAZARD GROUP  Are you confident that any non-GM organism, tissue, cell, body aponent thereof covered by this assessment cannot potentially pause human diseases?  3:1.1. If No, can any non-GM organism, tissue, cell, body fluid, exthereof cause human disease and potentially be a hazard to hurst spread to the community and for which there is usually effective treatment available?  3:1.2. If No, can any non-GM organism, tissue, cell, body fluid, exthereof cause severe human disease and potentially be a serious that may spread to the community, where effective prophylaxis not be available?  Do any of the materials contain pathogens or toxins covered by Security Act?  TIE: PLEASE READ CAREFULLY  must only answer 'YES' to question 3.1 if you believe that you have sufficiency.	r fluid, pose a xcreta nans be prop xcreta or tre	excreta on threat to or any concur is unlike hylaxis or or any concurd to humbatment mathematical information	mponer ely to mponer ans anc ay or m	ant	Yes* - Cla   No   Yes - Cla   No   Yes - DO   Onsult the	O NOT USE DSO  NOT USE DSO  A NOT USE DSO  A caterial(s) covered

hazard rating) should normally be handled in CL1 facilities (minimum level of containment), and likewise HG2 in CL2 facilities. All projects using HG1 and/or HG2 biological material(s) will be carried out under Containment level 2 (CL2) within the CL2 CBE Tissue Engineering Laboratory Unit or within the CL2 CBE Laboratory Unit at Holywell for reasons supplementary to worker protection; this includes the need to ensure research material protection/integrity (e.g. the use of a Class II safety cabinet) and to impose a quality assurance discipline.

4.	All relevant parts of this section must be complet	ed				
NATURE OF THE WORK	TISSUES, CELLS, BODY FLUIDS OR EXCRETA					
S.	4.1. If human or animal tissues, cells, body fluids	THE PARTY OF THE P	OT be use	ed then hatch h	ere 🗆 and proceed to Q4	1.8
0	4.2. Will any culturing of the material described in		□Yes			
∄	take place? If Yes, describe which cell(s) will be cu	iltured and	⊠No			
声	<ul><li>under what conditions.</li><li>4.3. If culturing, could HIV permissive cells be pre</li></ul>	sont*?				
0	If Yes, describe the cells and for how long these cu		□Yes			
	allowed to grow.	areares will be	⊠No			
	4.4. If culturing, what is the maximum volume of	culture	Per vess	el:	Number of vessels:	N/D
1)	grown?		N/R			N/R
	4.5. Will the tissues, cells, body fluids or excreta		□Yes			
	manipulated in any way that could result in the c		⊠No			
	of adventitious biological agent present? If Yes, e. 4.6. Will any of the tissues, cells or fluids be dona				one compared the authorization and	
	your colleagues working in or with access to the l		Yes□ N	o⊠		
×	4.6.1. If Yes, detail who will provide these					
						N/R
	4.6.2. If Yes, detail how the materials will be u	ised and the				
	special risks involved*					N/R
	4.6.3. If Yes, provide justification for not using					
	another safer source e.g. National Blood Servi 4.6.4. If Yes, how will confidentiality be assure					N/R
	4.0.4. If Tes, flow will confidentiality be assure	su:				N/R
	4.6.5. If Yes, has written consent been obtained	ed from the	•			
	donor?					N/R
	4.6.6. If Yes, has Ethics Committee approval b	een obtained?	Yes□ No			
	*NOTE 1: If unsure seek advice. Refer to CBE Code of Pi	ractice for details o	on addition	al precautions.		
	**NOTE 2: Workers MUST NEVER culture, deliberately					
	otherwise associated with the experimental work. This serious consequences as cells would essentially circums				HE 20 HA [1] 1 HA TAN BANGAN HANGAN [1] 1 HANGAN	otentially
	serious consequences as cens would essentially circum	vent the normal pr	otection of	the illinune syst	em.	
	BIOLOGICAL AGENTS (i.e. micro-organisms such	as bacteria, viru	ises, fungi	. microscopic e	ndoparasites)	
	If non-Genetically Modified biological agent will N					
	4.8. Describe ALL route(s) of infection (relevant	Name of agen		Route(s)	Minimum infectious	dose
	to the laboratory setting) and the minimum	3		•		
	infectious dose(s), if known					
,e.v.	4.9. What is the highest concentration and	Per experimer	it:	Total stored:		
	volume of agent(s) to be worked with?					
	4.10. Are there any known drug resistances amongst the strains to be used? <i>If Yes, explain</i>					
	what these are and the consequences					
	4.11. What forms of agent will be used e.g.					
	spores, vegetative forms and are there any				Sand and Sand of the	
	issues over the robustness of these particular				. 7	
	forms e.g. resistance to disinfectants or					
	increased stability on dry surfaces?  4.12. What will be the most hazardous					
	procedure involving the use of this material?					
(1)	All questions in this section must be answered a	nd further deta	ls supplie	d when indicat	ed	

Risk		If Yes, how will this be controlled?	Reference to SOPs/ other documentation
5.1. Might infectious droplets, aerosols or splashes be created, either deliberately or by accident?	□ Yes ⊠ No	For e.g., will a safety cabinet or any other form of Local Exhaust Ventilation be required? Are there specific requirements for room ventilation or temperature control?	Sealed vial, will not be opened fo transfer to storage
5.2. Will this material be transported within the laboratory e.g. between BSC & incubator?	☐ Yes ⊠ No	Detail the containment measures which will be used to prevent or contain accidental splashes or spills.	Storage only, no cell culture work
5.3. Will this material (including waste) be transported locally between sites on campus but outside the laboratory?	□ Yes ⊠ No	Detail the containment measures which will be used to prevent or contain accidental splashes or spills.	Storage only, if disposal of the vial is required this will be done within the laboratory according to loca biological waste procedures
5.4. Will material(s) listed in sections 2.2 or section 2.3 be shipped to organisations elsewhere in the UK or abroad?  *Refer to WHO guidance for transport of infectious substances: http://apps.who.int/iris/bitstream/10665/149288/1/WHO HSE GCR 2015.2 eng.pdf?ua=1	□ Yes ⊠ No	Provide details of material(s) to be shipped.(include secondary hazardous substances eg dry ice) Provide details of mode of transport eg road, rail, air, sea, postal. *Provide details of the packaging. If material is classified under the dangerous goods regulation, it must be packaged and labelled in compliance with its UN classification and associated packing instruction.	*Provide reference to relevant Packing Instruction
5.5. Will this material be received from organisations elsewhere in the UK or abroad?	☐ Yes ⊠ No	Provide details of the material to be received. What steps will be taken to ensure that the material is correctly packaged.	
5.6. Will this material be stored?	⊠ Yes □ No	Provide details of how, where and in what this material will stored. If LN2 describe the additional precautions in place.	The cryovial will be stored in the CBE cryobank location B7/R3/BXA1 accordance with SOP013 (Safe Use and Maintenance of Liquid Nitroge Stores) which describes additional precautions in place.
<ul><li>5.7. Will infectious material be centrifuged?</li><li>5.8. Are biological samples to be</li></ul>	☐ Yes ☑ No	Confirm whether sealed rotors and buckets will always be used  Describe where the rotors/buckets will be opened  Describe the procedures in place to deal with leaks or spillages in the centrifuge or rotor  Confirm what type of incubator (e.g. shaking or	
cultured in an incubator?  5.9. Are sharps to be used at any stage during this activity?	<ul><li>✓ No</li><li>✓ Yes</li><li>✓ No</li></ul>	static) will be used and describe the measures used to prevent and contain spillages  Describe the sharps, justify their use and describe the precautions in place to protect the user and others from injury	
5.10. Are animals to be used in this project?  (If Yes, describe procedures involved, if shedding is possible and additional precautions or training required)	☐ Yes ☑ No	Procedures: Describe what procedures will be undertaken (e.g. inoculation of animals, harvest of tissues), who will perform the work and where.  Shedding: Confirm if shedding of viable biological agent is possible (eg at site of inoculation, in faeces or urine) If Yes, detail the routes of shedding, risk periods and additional precautions to control	

			exposure.		
			Additional Precautions: Provide d additional precautions necessary training required for those handli	and any additional	9
	5.11. Will a fermenter/bioreactor be used to culture a biological agent or material?	☐ Yes	Confirm the size, type and location Describe any supplementary continger required (e.g., the use of a BSC of	ainment measures	
(r 54	5.12. Is there any stage within the experimental procedures when an infectious material is inactivated (other than for disposal)?	☐ Yes ⊠ No	Describe how will this be done an happen to the material	d what will then	
	5.13. Is there any of the following to be used in conjunction with this project?  If Yes, provide details	□ Yes ⊠ No	□Liquid nitrogen □Ionising radiation □Carcinogens/mutagens □Toxins □Lone working	* , , , , , , , , , , , , , , , , , , ,	
	5.1.4. Are there any conditions associated with the hazards described in section 5.13 that require additional control measures?	☐ Yes 図 No	Describe the control measures red hazards e.g. avoiding incompatible disinfectants (e.g. Virkon) or haza decomposition associated with his e.g. autoclaving	ilities with rdous product	
			1	2	
6.	All questions in this section must be answ	vered			
PPE AND	Control measure	Details			Reference to SOPs/ other documentation
PPE AND HYGEINE	<ul><li>6.1 When will gloves be worn?</li><li>6.2 What type and where will they be stored?</li><li>6.3 When will laboratory coats be worn</li></ul>	During all a Purple nitr LN2 work (	SOP037 - Use of Personal Protective Equipment (PPE)		
	and what type are these?  6.4 Where will lab coats be stored and what are the arrangements for cleaning	Lab entry (	e white laboratory coat worn du (First change room), arrangemen escribed in SOP037	*	Equipment (112)
	or disposal?  6.5 Is any other type of PPE to be used?  If Yes, provide details	Refer to SC			
	6.6 Describe the lab hygiene facilities available and where they are located		ning and eye wash stations locat main lab entry points	ed at lab entry	# · · · · · · · · · · · · · · · · · · ·
20	All questions in this section must be answ	vored			tally a his formation
7.					
\$	7.1. How will waste be treated prior to d				
WASTE	(Note that all differently treated wastes must be included e.g. if some liquid is autoclaved, but others not, then describe both)	Treatment	t prior to disposal	Is the treatment validated?	Reference to SOPs/ other documentation
	Liquid waste .	SOP003 "D All waste v and only p	contamination according to Disposal of Biological Waste" will be labelled appropriately rocessed by those persons a the project to ensure correct goccurs.	⊠Yes □No	SOP003 -Disposal of Biological (Healthcare) Waste
	Solid waste	SOP003 "D All waste v and only p involved in processing	Decontamination according to Disposal of Biological Waste" will be labelled appropriately processed by those persons in the project to ensure correct goccurs  121°C for 15 mins (under	⊠Yes □No	SOP003 - Disposal of Biological (Healthcare) Waste. SOP024 - Maintenance of

	Treatme accordin Systec V	racuum) CYCLE#4 Int Cycle (4) is validating to SOP024 "Mainto X-95 Autoclave CBEO In is conducted by aror.	enance of 144". Annual		Systec VX-95 Autoclave CBE044.
Other (specify)		8		□Yes □No	2
7.2. If waste is to be autoclaved confirm t	the follow	ing:			
All cycles have been validated for the actual load types used?		es X No □ o	f Yes, documei f the validation vailable	ntary evidence n must be	Annual validation is conducted by an external contractor, records of validation are held by CBE Laboratory Manager.
The successful completion of every load is checked prior to disposal?	, Y	es X No 🗆	12048		Autoclave tape monitoring and operator checks and records successful cycle completion
7.3. How will liquid waste be disposed of	?				
To drain?	Y	es X No □			After 1% Virkon decontamination for 24 hours, waste is poured down the drain with copious amounts of water. Refer to SOP003 "Disposal of Biological Waste"
As solid waste?	Υ	es □ No X			
Other (specify)?	Y	'es □ No □			
7.4. How will solid waste be disposed of?					
Categorisation		Waste stream: Colour Code	Disposal me	ethod	
☐ Sharps		Orange	sterilisation clinical wast	nge lidded sharps if known or poter e disposal (incine	ntially infected > ration)
☐ Sharps contaminated with cytotoxic or cytostatic material		Purple	disposal (inc	cineration @ 1000	
☑ Human body parts, organs, including blo and blood preserves and excreta that have pre-treated before leaving the site		Orange	Yellow/Orar tissue bins > #Human tiss separate co	or sterilisation in nge lidded rigid or clinical waste dis sue waste must b ntainers from no d'HTA waste'	ne way sealed sposal (incineration) ne placed in
☐ Animal body carcasses or recognisable path that have been pre-treated before leaving		Orange	Yellow/Orar	or sterilisation in nge lidded rigid or clinical waste dis	
☐ Potentially or known infected lab waste contaminated or potentially contaminated		Purple	Yellow/Purp disposal (inc		pags > clinical waste

TOTAL PROPERTY OF THE PARTY OF	cytotoxic or cytost pre-treated before		ial that have NOT been e site				
Contraction of the last	have NOT been pro	e-treated b	cted lab wastes that before leaving the site	Yellow	disposal (incineratio		
THE PROPERTY OF THE PARTY OF TH	☐ Infected or pote have been pre-trea		ected lab wastes that e leaving site	Orange	Disinfection or sterilisation in the lab site > orange clinical waste bags > clinical waste disposal (incineration)		
THE RESERVE THE PERSON NAMED IN	All questions in th	is section	must be answered				
The second second			enance and monitoring	g regimes in place for	the following laborato	ry equipment?	
STATE OF THE PARTY	If Yes, detail	frequency	Inspection, servicing	Cleaning/ disinfection	Monitoring/ Alarms	Reference to SOPs	N/R
	Centrifuges	⊠Yes □No	Annual	weekly	weekly	SOP015 - Use and maintenance of BOECO U-32R Bench top Centrifuge	
	BSCs	⊠Yes □No	Annual	weekly	daily	SOP009 - Use and Maintenance of the HERAsafe KS Class II Biological Safety	
Contract of the Contract of th	Autoclaves	⊠Yes □No	Annual	weekly	Daily	SOP024 - Use and Maintenance of Systec VX Autoclave No CBE044 / 45	
Charles and the second second	Incubators	⊠Yes □No	Annual	weekly	Daily	SOP053 - Use and Maintenance Sanyo MCO-18AIC CO2 Incubator v2.	
	LN2 Stores	⊠Yes □No	weekly		Twice weekly	SOP013 - Safe Use and Maintenance of Liquid Nitrogen Stores	
The state of the s	Freezers	⊠Yes □No	Annual	weekly	weekly	SOP016 Use and Maintenance of Fridges & Freezers	. 🗵
THE RESIDENCE OF THE PERSON OF	Fridges	⊠Yes □No	Annual	weekly	weekly	SOP016 Use and Maintenance of Fridges & Freezers	
A COLUMN CONTRACTOR	Others (specify)	□Yes □No	n 16.	II		, , ,	
and the same of	All questions in th		must be answered				
AND DESCRIPTION OF THE PERSONS ASSESSMENT			workers under taken s	afety training for wor	king with hazardous or	potentially hazardous	
	biological material Name of research	s and ager	its at CL2?	Date training completed or will be completed	If No ,please state	<b>.</b>	
	Junaid Ali		⊠Yes □No	May 2016			
	Elizabeth Ratcliffe		⊠Yes □No	Oct 2008			
			□Yes □No		5 Y		
			☐Yes ☐No		, ""		
1			☐Yes ☐No		1		

Name of researcher			Date HTA training completed or will be completed		If No ,please state	e why			
				Induction		On-line	In-house		
	Elizabeth Ratcliffe	⊠Yes □	No	25/05/2			26/06/2017		
,	Junaid Ali	□Yes ⊠		,				Not working with material, the mat only stored, if the plans for the rese to work with the material they will undertake HTA tra before doing so	erial is re are archer
76		□Yes □	No		20	32 ti <sub>2.3</sub>	1		
-	E	□Yes □				×	3	,	8
	* 1	☐Yes ☐	No						
10. EI	All questions in this section must l			illago of i	ofostio	us ar natantial	ly infactious mat	orial	
MER	Equipment Equipment	n dealing w	iui sp	mage of fi		ence to SOPs	iy imectious mat	eriai	N/R
GENCY PR	Within the BSC	,	⊠Ye	s□No	SOP0 Class			ne HERAsafe KS	N/N   ⊠
EMERGENCY PROCEDURES	Within the centrifuge	Vithin the centrifuge		s□No	Bencl	15 - Use and m n top Centrifug 38 - Biological	naintenance of BOECO U-32R ge		
ES	Within the laboratory but outside any primary control measure e.g. BSC		⊠Ye	s□No	SOP0	SOP038 - Biological Spill Response			. 🗆
	Outside the laboratory		⊠Ye	s□No	SOP0	38 - Biological	Spill Response		$\boxtimes$
	10.2. Describe the procedures in	n place for	an acc	idental ex	kposure	9		Reference to SO	Ps
	Immediate action		la Si U bi al U	boratory gns are po nit to ena ological ( so display nit to adv	within osted the work of the with the work of the with the work of	I Spill kits are I the CBE Labora hroughout the rkers to locate emical) spill kit each laboratory spill response ( g procedures.	Laboratory the nearest s. Posters are within the	SOP038 - Biologi Spill Response	cal
×	When and whom to report the inci	dent			-	aking the area nagement	safe, local	SOP038 - Biologi Spill Response	cal
	All questions in this section must be	ne answere	d						
11.	An questions in this section must be	A GIIBWEIC							
AC								Reference/SOP	
ACCESS	11.1. Is the lab(s) adequately separ from other areas (e.g. offices)?  If No, explain	ated	ld.	s 🗆 No		" " " " " " " " " " " " " " " " " " "	* * * * * * * * * * * * * * * * * * *	\$ .	
	11.2. Is the lab(s) or other work are shared with other users not involve project?  If Yes, explain who and what proce in place to control any risk to them.	ed in the dures are	The c CBE, safe cryol	all users g working v bank. Only ss to the c	go thro vithin C y autho cryobar		training for cally the users can gain	SOP013 - Safe Us Maintenance of Nitrogen Stores	
	11.3. Describe the measures in place ensure that hazardous biological agmaterial is secure		auth			l at all times ar ers can gain ac		SOP013 - Safe Us Maintenance of Nitrogen Stores	

12.	All questions in this section must be answered			
OCCUPATIONAL	12.1. All workers involved with handling unscreened recommended to have Hepatitis B immunisation. H			nmunized? □Yes ⊠No
NAL	12.2. Is health surveillance required?			□Yes ⊠No
	All questions in this section must be answered			
13. 1		N/V	If Vac mustide Lieuwer No. 120	-77
NOTIFICATIONS	13.1. Are any of the cells, tissues or fluids covered by the Human Tissue Act (HTA) under the University H Licence?	SATER AND A STATE OF THE SEASON STATE AND ADDRESS OF THE SEASO	If Yes, provide Licence No. 125	¥
TIONS	13.2. Are any of the cells, tissues or fluids obtained from a HTA licensed biobank with REC approval for generic research use?	□Yes ⊠No	If Yes, provide details (includir evidence of approval.	ng dates) and reference to
	13.3. Does this work have ethical approval from a recognised NHS Research Ethics Committee?	□Yes ⊠No	If Yes, provide details (includir evidence of approval	ng dates) and reference to
2	13.4. Does any of the work require approval from the University Ethical Committee?	ne □Yes ⊠No	If Yes, provide details (includir evidence of approval.	ng dates) and reference to
e P	13.5. Do any of the materials require approval for u from the UK Stem Cell Bank Steering Committee (MRC)? (e.g. embryonic stem cells sourced from UK source but not available through the UK Stem Cell Bank)	XNO.	If Yes, provide details (includir evidence of approval.	ng dates) and reference to
z.	13.6. Do any of the materials or biological agents list require any other licenses? (e.g. HSE notification under COSSH; Home Office notificate under anti-terrorism, crime and security act; Defra/SAPO license for import of animal products and pathogens etc.	□Yes	If Yes, provide details (includir evidence of approval.	ng dates) and reference to
-	All relevant approvals must be completed before v	work is started		
14.	All relevant approvals must be completed before t	work is started		
APPROVALS	For work involving HG1 biological agents or mater Manager or an authorised, designated member of C to the University Safety Office. NOTE: Explicit approand the University Biological Safety Officer before v	CBE staff before oval will also be	the work begins. A signed copy required from the Departmenta	of this form must be sent
SI	For work with HG2 biological agents or materials: Advisor and the University Biological Safety Officer			ental Biological Safety
v	For all work involving HTA 'Relevant Material': If y the departmental Person Designate.  If the biological agent has been Genetically Modifie			
	submitted with the GMO risk assessment to the De GM Safety Committee for final approval.	partmental Bio	logical Safety Advisor and both f	forms forwarded to the LU
	NAME: SIGNA	ATURE:		DATE:
	Departmental Quality Manager or other authorised personnel	1 Ka	J	11.06.02018

2.	Departmental Person Designate (as applicable):	N-Z	18/6/2018
3.	Departmental Biological Safety Advisor:		
,			
4.	University Biological Safety Officer (or Deputy):		